FDA issued a revised draft guidance on medical gases that meet the definition of a drug and are subject to applicable CGMP requirements, which supersedes earlier guidance issued in May 2003. The revised guidance is expected to reduce the regulatory compliance burden for the medical gas industry by providing clear, up-to-date, detailed recommendations regarding CGMP issues that have been the subject of industry questions and reported to Congress.
[/membership][membership level=”0,4″][The content continues for paid members only.]
Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
